Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 1;10(1):96-98.
doi: 10.1001/jamacardio.2024.4657.

Semaglutide Eligibility Across All Current Indications for US Adults

Ivy Shi  1   2 , Sadiya S Khan  3   4 , Robert W Yeh  1   5 , Jennifer E Ho  5 , Issa J Dahabreh  1   6   7   8 , Dhruv S Kazi  1   5
Affiliations

Semaglutide Eligibility Across All Current Indications for US Adults

Ivy Shi et al. JAMA Cardiol. .
No abstract available

Plain language summary

This cross-sectional study uses National Health and Nutrition Examination Survey data to examine the number of US adults eligible for semaglutide across all current indications.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Khan reported grants from the National Heart, Lung, and Blood Institute outside the submitted work. Dr Ho reported grants from the National Institutes of Health during the conduct of the study. Dr Dahabreh reported a contract with the Patient-Centered Outcomes Research Institute and grants from the National Institutes of Health during the conduct of the study. Dr Kazi reported grants from the National Heart, Lung, and Blood Institute, American Heart Institute, Agency for Healthcare Research and Quality, Patient-Centered Outcomes Research Institute, and Institute for Clinical and Economic Research outside the submitted work. No other disclosures were reported.

References

    1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. ; SELECT Trial Investigators . Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 - DOI - PubMed
    1. Harris E. Poll: roughly 12% of US adults have used a GLP-1 drug, even if unaffordable. JAMA. 2024;332(1):8. doi:10.1001/jama.2024.10333 - DOI - PubMed
    1. National Center for Health Statistics . National Health and Nutrition Examination Survey, 2015-2020. Accessed August 1, 2024. https://wwwn.cdc.gov/nchs/nhanes/Default.aspx
    1. Wadden TA, Bailey TS, Billings LK, et al. ; STEP 3 Investigators . Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831 - DOI - PMC - PubMed
    1. Aroda VR, Ahmann A, Cariou B, et al. . Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45(5):409-418. doi:10.1016/j.diabet.2018.12.001 - DOI - PubMed

LinkOut - more resources